Contrast-induced nephropathy: What are the true clinical consequences?

被引:113
作者
Rudnick, Michael [1 ]
Feldmant, Harold [2 ]
机构
[1] Presbyterian Med Ctr, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2008年 / 3卷 / 01期
关键词
D O I
10.2215/CJN.03690907
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Observational studies have demonstrated that short- and long-term mortality is increased in patients who develop contrast-induced nephropathy (CIN). The more clinically relevant questions, and the objectives of this review, are whether CIN is causally related to mortality, and to what extent could mortality in patients undergoing contrast procedures be reduced by preventing CIN. Design, setting, participants, & measurements: A literature review was conducted, focusing on observational studies that assessed factors associated with mortality in patients with CIN. Results: The deaths of some patients with CIN are complicated by factors that cannot be directly related to CIN, such as liver disease, sepsis, respiratory failure, bleeding, etc. However, it is plausible that CIN contributes to cardiovascular causes of death in patients with CIN. Conclusions: At the very least, CIN is a marker for increased mortality. More carefully designed prospective studies are needed to fully elucidate the relationship between CIN and death. In the absence of data disproving a causal relationship between CIN and death in all subgroups, reducing its incidence should remain a goal in clinical practice as well as a target for future research.
引用
收藏
页码:263 / 272
页数:10
相关论文
共 17 条
[11]   The prevention of radiocontrast-agent-induced nephropathy by hemofiltration [J].
Marenzi, G ;
Marana, I ;
Lauri, G ;
Assanelli, E ;
Grazi, M ;
Campodonico, J ;
Trabattoni, D ;
Fabbiocchi, F ;
Montorsi, P ;
Bartorelli, AL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (14) :1333-1340
[12]   N-acetylcysteine and contrast-induced nephropathy in primary angioplasty [J].
Marenzi, Giancarlo ;
Assanelli, Emilio ;
Marana, Ivana ;
Lauri, Gianfranco ;
Campodonico, Jeness ;
Grazi, Marco ;
De Metrio, Monica ;
Galli, Stefano ;
Fabbiocchi, Franco ;
Montorsi, Piero ;
Veglia, Fabrizio ;
Bartorelli, Antonio L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (26) :2773-2782
[13]   Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality [J].
McCullough, PA ;
Wolyn, R ;
Rocher, LL ;
Levin, RN ;
ONeill, WW .
AMERICAN JOURNAL OF MEDICINE, 1997, 103 (05) :368-375
[14]   N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up [J].
Miner, SES ;
Dzavik, V ;
Nguyen-Ho, P ;
Richardson, R ;
Mitchell, J ;
Atchison, D ;
Seidelin, P ;
Daly, P ;
Ross, J ;
McLaughlin, PR ;
Ing, D ;
Lewycky, P ;
Barolet, A ;
Schwartz, L .
AMERICAN HEART JOURNAL, 2004, 148 (04) :690-695
[15]   Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention [J].
Rihal, CS ;
Textor, SC ;
Grill, DE ;
Berger, PB ;
Ting, HH ;
Best, PJ ;
Singh, M ;
Bell, MR ;
Barsness, GW ;
Mathew, V ;
Garratt, KN ;
Holmes, DR .
CIRCULATION, 2002, 105 (19) :2259-2264
[16]   Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients [J].
Shlipak, MG ;
Heidenreich, PA ;
Noguchi, H ;
Chertow, GM ;
Browner, WS ;
McClellan, MB .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (07) :555-562
[17]   Infarct size limitation: Acute N-acetylcysteine defense (ISLAND trial): Preliminary analysis and report after the first 30 patients [J].
Sochman, J ;
Vrbska, J ;
Musilova, B ;
Rocek, M .
CLINICAL CARDIOLOGY, 1996, 19 (02) :94-100